-
The pharmaceutical industry has invented a new art form: finding ways to make their wares seem like joyous must-have treatments, while often minimizing lackluster efficacy and risks.
-
The FDA considers plants that have gone more than five years without an inspection to be a significant risk. Officials say the work has been hampered by difficulties recruiting and retaining inspectors.
-
The school district is self-insured, meaning it foots the bill for the health care costs of employees. As many as 3,500 employees may be affected by insulin price increases over the past 20 years.
-
As Congress pushes for Medicare to cover payment for anti-obesity drugs, Denmark — home of Ozempic maker Novo Nordisk — has limited coverage of the drug after cost overruns “emptied all the money boxes in the entire public health system.”
-
A flood of litigation — with plaintiffs like small businesses, drugmakers, and hospitals challenging regulations — could leave the country with a patchwork of disparate health regulations.
-
The failed dissolution of Glenmark Pharmaceuticals' extended-release capsules may cause high potassium levels, also known as hyperkalemia, which can result in irregular heart beat that can lead to cardiac arrest.
-
President Joe Biden is campaigning on his efforts to cut drug costs for Medicare patients. But independent pharmacists say one strategy makes it unaffordable for them to keep some brand-name medicines in stock.
-
The makers of Ozempic and Mounjaro charge charge around $1,000 a month for the drugs, and insurers are reluctant to pick up the tab. Often, low-income patients have to resort to less effective treatments.
-
The FDA told Amgen to test whether a quarter-dose of sotorasib worked as well as the amount on the label. It did, but the biotech is sticking to the higher dose, which earns it an extra $180,000 a year per patient.
-
A study by the Rand Corp., a nonpartisan research organization, found that, across all drugs, U.S. prices were 2.78 times higher than the prices in 33 OECD countries. The gap was even larger for brand-name drugs.